Full-Time

Compliance Specialist

Analytical Development

Updated on 9/3/2026

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

Compensation Overview

$64k - $79.6k/yr

Albany, NY, USA

In Person

Bachelor's, Master's

Category
Biology & Biotech (1)

Get referred to Curia

See people who can refer or advise you

Requirements
  • Develop and maintain a strong command of standard operating procedures, current good manufacturing practices, and associated regulations.
  • Develop an understanding of the function and basic operation of analytical equipment and techniques.
  • Possess an MS or BS degree in a technical discipline such as science or engineering, or relevant laboratory or chemical manufacturing experience in lieu of education.
  • Have an MS degree and at least one year of industrial current good manufacturing practice experience in an FDA-regulated pharmaceutical environment, or a BS degree and at least three years of such experience; relevant experience may substitute for education.
  • Demonstrate proficiency in technical writing, including quality events, change controls, standard operating procedures, protocols, and reports.
  • Have knowledge of Food and Drug Administration and International Council for Harmonisation guidance for pharmaceuticals.
  • Pass a background check and drug screen.
  • Pass Occupational Health Screening if required.
Responsibilities
  • Monitor compliance in the Analytical laboratories and actively participate in resolving quality issues.
  • Identify quality system improvements, recommend methods to increase product or service quality, and participate in implementing improvements.
  • Assist Analytical staff with change control and corrective and preventive action processes, write deviations and investigations, and identify and communicate areas of concern to management.
  • Track and manage timelines for analytical quality events and initiatives, coordinate efforts to meet timelines, and assist with extension requests when necessary.
  • Coordinate periodic review and revision of standard operating procedures.
  • Review or approve, where applicable, standard operating procedures, material specification forms, test methods, instrument qualification protocols and reports, and vendor repair or calibration reports.
  • Assist Analytical staff with reviewing and approving equipment qualification documentation, including protocols and reports.
  • Assist Analytical staff with training programs for new hires and ongoing departmental compliance awareness.
  • Assist during regulatory, client, and internal audits, including tours of Analytical laboratory areas.
  • Coordinate Analytical responses to regulatory, client, and internal audits and engage relevant subject matter experts when necessary.
  • Perform duties safely in accordance with the Curia Safety Program, Occupational Safety and Health Administration requirements, Food and Drug Administration regulations, and applicable federal, state, and local regulations.
  • Communicate with Analytical personnel and development chemists, Small Scale Manufacturing chemists, Quality and Regulatory personnel, Receiving personnel, maintenance and engineering personnel, information systems personnel, and designated management members.
  • Participate in self-development activities and exhibit safety awareness and safe work practices.
  • Perform other related duties reasonably assigned in the course of business.
Desired Qualifications
  • Experience with analytical instrument qualification and conducting investigations for quality events.

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.